Loading the security overview…
Where the tokens are
| Quarter | EPS | EPS vs year ago | Revenue | Revenue vs year ago |
|---|---|---|---|---|
| Q2 FY19ended Jun 30, 2019 | −$0.07 | — | $157.00K | −98.3% |
| Q1 FY19ended Mar 31, 2019 | −$0.04 | — | — | — |
| Q4 FY18ended Dec 31, 2018 | −$0.06 | — | $1.48M | −65.4% |
| Q3 FY18ended Sep 30, 2018 | $0.01 | — | $40.79M | +50.1% |
| Q2 FY18ended Jun 30, 2018 | −$0.08 | — | $9.04M | +156.7% |
| Q1 FY18ended Mar 31, 2018 | −$0.04 | — | $8.20M | +186.9% |
| Q4 FY17ended Dec 31, 2017 | −$0.05 | — | $4.27M | −50.0% |
| Q3 FY17ended Sep 30, 2017 | — | — | $27.19M | +1025.2% |
| Q2 FY17ended Jun 30, 2017 | −$0.04 | — | $3.52M | — |
| Q1 FY17ended Mar 31, 2017 | −$0.05 | — | $2.86M | — |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss.
Figures describe Ascendis Pharma A/S shares, not any token. From Massive's standardised financials and the earnings calendar.
| Q4 FY16ended Dec 31, 2016 | −$0.04 | — | $8.54M | — |
| Q3 FY16ended Sep 30, 2016 | −$0.04 | — | $2.42M | — |